The UAE News web report: Now there are strong hopes that the COVID-19 will disappear from the world soon after the 90 per cent success rate of Pfizer vaccine and it was a great day for humanities when the US pharmaceutical giant announced it on Monday.
Pfizer on November 9 claimed that tests involving more than 40,000 people had provided results that were a “critical milestone” in the search for a vaccine. This news surfaced at a time when global COVID-19 surged past 50 million including 10 million coronavirus cases now in the United States alone.
Stock markets had already jumped after Democrat Joe Biden was called as the winner of the US presidential election on the weekend. They accelerated rapidly on the Pfizer vaccine news, with the Dow Jones Industrial Average up three percent at Monday’s close of trade.
An effective vaccine is seen as the best hope to break the cycle of deadly virus surges followed by severe restrictions across much of the world since COVID-19 first emerged in China late last year.
Breakthrough
“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis,” Pfizer chairman Albert Bourla said in a statement about Covid-19 vaccine.
The drug, being developed jointly with German firm BioNTech, is one of more than 40 candidate vaccines, but no other has yet made similar claims about its effectiveness.
The companies said they could pass the final hurdles for a US rollout later this month, and could supply up to 50 million doses of Covid-19 globally this year and up to 1.3 billion next year.
The scientific community reacted positively, with top US expert Anthony Fauci describing the results as “extraordinary.”
World Health Organization director Tedros Adhanom Ghebreyesus hailed the news about Pfizer vaccine as “encouraging” shortly after warning that the world “might be tired of Covid-19. But it is not tired of us.”
But others pointed out that no information had yet been disclosed about the ages of the participants in the trial.
“If a vaccine is to reduce severe disease and death, and thus enable the population at large to return to their normal day-to-day lives, it will need to be effective in older and elderly members of our society,” said Eleanor Riley, professor of immunology and infectious diseases at the University of Edinburgh with reference to Covid-19 vaccine.
Also read: COVID-19 vaccine may be ready by year-end: WHO
Click here to read our Facebook page
